Director/PDMR Shareholding
30 September 2021 16:00 BST Transaction by Person Discharging Managerial Responsibilities Disclosure under Article 19 of the EU Market Abuse Regulation AstraZeneca PLC (the Company) announces that, on 30 September 2021, it was notified by Pascal Soriot, Chief Executive Officer, that, on 30 September 2021, Mr Soriot ceased to be beneficially interested in 231,922 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration. The attached notification, made in accordance with the requirements of the EU Market Abuse